To the Editor:
We read with great interest the article by Tselios, et al on mycophenolate mofetil (MMF) in nonrenal manifestations of systemic lupus erythematosus (SLE)1. The study suggested that this treatment is an efficacious alternative in refractory to standard-of-care of nonrenal manifestations of SLE in the long term1. However, some data are lacking to change our clinical practice. For instance, with regard to cutaneous lupus erythematosus (CLE) lesions, an improvement was observed at 6 and 12 months in 25.9% and 40.7% of patients without renal involvement, respectively, and at 6 and 12 months in 33.3% and 53.3% of patients with renal involvement, respectively1. Such a result is very interesting in our daily practice because of conflicting data in the literature, as indicated by the authors. However, we have a few comments on this article about …
Address correspondence to Dr. C. Bachmeyer, Service de Médecine Interne, Hôpital Tenon (AP-HP), 4 rue de la Chine, 75020 Paris, France. E-mail: claude.bachmeyer{at}tnn.aphp.fr